Related references
Note: Only part of the references are listed.
Article
Biochemistry & Molecular Biology
Alexandra C. Walls et al.
Summary: Breakthrough infections induce more potent and durable antibody responses compared to those in unvaccinated individuals, providing better protection against spike mutations in variants. Multiple exposures to SARS-CoV-2 antigen enhance the quality of antibody responses. Developing vaccines with broad sarbecovirus immunity is crucial for pandemic preparedness.
Article
Biochemistry & Molecular Biology
Pengcheng Han et al.
Summary: The study found that the omicron variant, unlike other variants, has a similar affinity to the human receptor ACE2 as the prototype variant. Multiple mutations in the omicron variant may compensate for both immune escape and transmissibility. The complex structures of the omicron and delta variants binding to ACE2 provide insights into how specific mutations affect the binding.
Article
Multidisciplinary Sciences
Raquel Viana et al.
Summary: The SARS-CoV-2 epidemic in southern Africa has experienced three distinct waves, driven by different variants. The recently identified Omicron variant has rapidly spread in South Africa and to numerous countries, raising global concern.
Article
Multidisciplinary Sciences
Naoki Iwanaga et al.
Summary: Researchers constructed an ACE2-human IgG1 fusion protein with mutations in the catalytic domain of ACE2, which significantly increased binding to SARS-CoV-2 spike protein and improved lung infection caused by the virus in vivo. This study suggests that MDR504 hACE2-Fc may be a promising candidate for the treatment or prevention of COVID-19 and emerging variants.
Article
Biotechnology & Applied Microbiology
Sylvia Rothenberger et al.
Summary: A trispecific DARPin protein called ensovibep has been found to inhibit multiple variants of SARS-CoV-2, including Omicron sublineages BA.1 and BA.2. Both animal and in vitro experiments have shown that ensovibep exhibits similar antiviral effects compared to standard monoclonal antibodies, suggesting it could be a promising new therapy against COVID-19.
NATURE BIOTECHNOLOGY
(2022)
Article
Multidisciplinary Sciences
Maya Imbrechts et al.
Summary: The study identified six monoclonal antibodies that can effectively neutralize various SARS-CoV-2 variants, including the omicron variant. In a hamster model, antibodies 3E6 and 3B8 demonstrated potent efficacy in curing infections even at lower doses, with intramuscular delivery of DNA-encoded 3B8 resulting in protective antibodies in vivo. These findings suggest promising potential for 3B8 as a candidate against COVID-19 and highlight advancements in identifying and delivering potent human antibodies.
Article
Biochemistry & Molecular Biology
Eric F. Pettersen et al.
Summary: UCSF ChimeraX is a powerful visualization program with enhanced performance and graphics, offering new tools and analysis features, support for various areas like virtual reality, and improved ease of use, along with an app store for researchers to contribute new tools.
Article
Immunology
Vincent Dussupt et al.
Summary: Multiple monoclonal antibodies targeting the RBD or NTD of the SARS-CoV-2 spike protein have potent cross-neutralizing activities against variants of concern, and when used in combination, they have complementary effects on viral neutralization and can protect against viral escape mutants.
Article
Multidisciplinary Sciences
Houriiyah Tegally et al.
Summary: The article describes a newly emerged lineage of SARS-CoV-2, 501Y.V2, characterized by eight mutations in the spike protein, which may result in increased transmissibility or immune escape. This lineage originated in South Africa and quickly became dominant in Eastern Cape, Western Cape, and KwaZuluNatal provinces within weeks.
Article
Immunology
Xiaojian Han et al.
Summary: This study developed an effective screening method that enabled the generation of NAbs specific to SARS-CoV-2 with high neutralizing activity within 15 days. These NAbs exhibited advanced neutralizing potency and high affinity against SARS-CoV-2.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Multidisciplinary Sciences
Kathryn M. Hastie et al.
Summary: Antibody-based therapeutics and vaccines are crucial in combating COVID-19, especially with mutations and transmission of SARS-CoV-2. An international consortium identified multiple RBD-directed antibody communities, providing a framework for selecting treatment cocktails.
Article
Cell Biology
Hyeseon Cho et al.
Summary: Research isolated 216 monoclonal antibodies from patients with COVID-19, with three potent antibodies neutralizing the Alpha and Beta variants of SARS-CoV-2. Bispecific antibodies designed through distinct mechanisms showed high efficacy in inhibiting virus infection, with one exhibiting over 100-fold higher potency than a monoclonal antibody cocktail and protecting against disease in hamster models.
SCIENCE TRANSLATIONAL MEDICINE
(2021)
Article
Microbiology
Jiri Zahradnik et al.
Summary: In vitro evolution of the SARS-CoV-2 spike protein receptor-binding domain successfully generated a high-affinity variant effective in inhibiting virus infection. Mutations present in more transmissible viruses were preferentially selected, and increased affinity to ACE2 was positively correlated with the incidence of RBD mutations in the population. The study also identified mutations with potential higher infectivity, and the high-affinity RBD variant showed efficacy in inhibiting infection in vitro and reducing clinical disease in a hamster model of SARS-CoV-2 challenge.
NATURE MICROBIOLOGY
(2021)
Article
Multidisciplinary Sciences
Ching-Lin Hsieh et al.
Article
Multidisciplinary Sciences
Christopher O. Barnes et al.
Article
Cell Biology
Bryan Howie et al.
SCIENCE TRANSLATIONAL MEDICINE
(2015)
